HLA-DR Frequency in Turkish Aplastic Anemia Patients and the Impact of HLA-DR2 Positivity in Response Rate in Patients Receiving Immunosuppressive Therapy
To the Editor:
Certain HLA haplotypes were found guilty for certain diseases, and aplastic anemia (AA) is reported to be one of them, especially for HLA-DR2
However, HLA-DR2 frequency in AA reached significance in only one study that contained a racially heterogeneous group. We retrospectively analyzed the results of HLA-DR typing in 26 Turkish AA patients who received either immunosuppressive therapy (IST) or HLA-matched sibling bone marrow transplantation (BMT). Nineteen were male and seven were female. Median age was 22 (range, 12 to 33). In the AA group, HLA-DR2 and -DR3 frequencies were 42.3% and 11.5%, respectively. Other HLA-DR frequencies are given in Table 1 . HLA-DR2 positivity was found significantly higher in patients with AA when compared with an unrelated healthy control group ( P = .02). All the patients and the control group (n = 230) were white. The relative risk of AA in DR2+ versus DR2-patients is 1.99 (with a 95% confidence interval of 1.19 to 3.32). Eighteen patients received IST and 8 received BMT. Of the 18 patients given IST, 4 4 % (8 patients) had either a complete remission (CR) (6 patients) or partial remission (PR) (2 patients). In DR2+ and DR2-patients, overall response rates were 66% (4 CR and 2 PR) and 22% (2 CR), respectively ( P = .029). On the contrary, in Nimer et al's study, there was no significant difference between HLA-DR2+ and -D R T patients in response to ATG therapy in a racially heterogeneous group. As a result, the incidence of HLA-DR2 was clearly increased in Turkish patients with AA. Response rate to IST was significantly higher in the DR2+ patients when compared with the DR2-patients. 
